drugset / Trial / NCT06078215

CERebrolysine Effect on Blood-brain Barrier in acUte Ischemic Stroke

NCT06078215

Phase 4 Unknown 350 enrolled Poznan University of Medical Sciences
RandomizedParallel-groupOpen-labelTreatment

Summary

The study investigates whether Cerebrolysin stabilizes blood-brain barrier integrity in a manner that can be monitored using serum levels of the principal tight junction proteins, e.g., occludin (OCL), claudin-5 (CLN), and zonula occludens-1 (ZO-1), or other molecules known to be involved in BBB degradation, e.g., S100B and whether it protects against hemorrhagic transformation in ischemic stroke patients after reperfusion therapy (i.e. thrombolysis and/or mechanical thrombectomy).

Timeline

Start
2023-01-10
Primary completion
2025-01-31
Completion
2025-03-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cerebrolysin Peptide 30 ml Intravenous

Indications